Recent advances in GPR35 pharmacology; 5-HIAA serotonin metabolite becomes a ligand
Arch Pharm Res. 2023 May 25. doi: 10.1007/s12272-023-01449-y. Online ahead of print.ABSTRACTGPR35, an orphan receptor, has been waiting for its ligand since its cloning in 1998. Many endogenous and exogenous molecules have been suggested to act as agonists of GPR35 including kynurenic acid, zaprinast, lysophosphatidic acid, and CXCL17. However, complex and controversial responses to ligands among species have become a huge hurdle in the development of therapeutics in addition to the orphan state. Recently, a serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA), is reported to be a high potency ligand for GPR35 by inve...
Source: Archives of Pharmacal Research - May 25, 2023 Category: Drugs & Pharmacology Authors: Dong-Soon Im Source Type: research
Recent advances in GPR35 pharmacology; 5-HIAA serotonin metabolite becomes a ligand
Arch Pharm Res. 2023 May 25. doi: 10.1007/s12272-023-01449-y. Online ahead of print.ABSTRACTGPR35, an orphan receptor, has been waiting for its ligand since its cloning in 1998. Many endogenous and exogenous molecules have been suggested to act as agonists of GPR35 including kynurenic acid, zaprinast, lysophosphatidic acid, and CXCL17. However, complex and controversial responses to ligands among species have become a huge hurdle in the development of therapeutics in addition to the orphan state. Recently, a serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA), is reported to be a high potency ligand for GPR35 by inve...
Source: Archives of Pharmacal Research - May 25, 2023 Category: Drugs & Pharmacology Authors: Dong-Soon Im Source Type: research
Recent advances in GPR35 pharmacology; 5-HIAA serotonin metabolite becomes a ligand
Arch Pharm Res. 2023 May 25. doi: 10.1007/s12272-023-01449-y. Online ahead of print.ABSTRACTGPR35, an orphan receptor, has been waiting for its ligand since its cloning in 1998. Many endogenous and exogenous molecules have been suggested to act as agonists of GPR35 including kynurenic acid, zaprinast, lysophosphatidic acid, and CXCL17. However, complex and controversial responses to ligands among species have become a huge hurdle in the development of therapeutics in addition to the orphan state. Recently, a serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA), is reported to be a high potency ligand for GPR35 by inve...
Source: Archives of Pharmacal Research - May 25, 2023 Category: Drugs & Pharmacology Authors: Dong-Soon Im Source Type: research
Recent advances in GPR35 pharmacology; 5-HIAA serotonin metabolite becomes a ligand
Arch Pharm Res. 2023 May 25. doi: 10.1007/s12272-023-01449-y. Online ahead of print.ABSTRACTGPR35, an orphan receptor, has been waiting for its ligand since its cloning in 1998. Many endogenous and exogenous molecules have been suggested to act as agonists of GPR35 including kynurenic acid, zaprinast, lysophosphatidic acid, and CXCL17. However, complex and controversial responses to ligands among species have become a huge hurdle in the development of therapeutics in addition to the orphan state. Recently, a serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA), is reported to be a high potency ligand for GPR35 by inve...
Source: Archives of Pharmacal Research - May 25, 2023 Category: Drugs & Pharmacology Authors: Dong-Soon Im Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 May;46(5):438-447. doi: 10.1007/s12272-023-01448-z. Epub 2023 Apr 25.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazid...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 May;46(5):438-447. doi: 10.1007/s12272-023-01448-z. Epub 2023 Apr 25.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazid...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 May;46(5):438-447. doi: 10.1007/s12272-023-01448-z. Epub 2023 Apr 25.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazid...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 May;46(5):438-447. doi: 10.1007/s12272-023-01448-z. Epub 2023 Apr 25.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazid...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 May;46(5):438-447. doi: 10.1007/s12272-023-01448-z. Epub 2023 Apr 25.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazid...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 May;46(5):438-447. doi: 10.1007/s12272-023-01448-z. Epub 2023 Apr 25.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazid...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 May;46(5):438-447. doi: 10.1007/s12272-023-01448-z. Epub 2023 Apr 25.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazid...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 May;46(5):438-447. doi: 10.1007/s12272-023-01448-z. Epub 2023 Apr 25.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazid...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 May;46(5):438-447. doi: 10.1007/s12272-023-01448-z. Epub 2023 Apr 25.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazid...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 May;46(5):438-447. doi: 10.1007/s12272-023-01448-z. Epub 2023 Apr 25.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazid...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
Arch Pharm Res. 2023 May;46(5):438-447. doi: 10.1007/s12272-023-01448-z. Epub 2023 Apr 25.ABSTRACTGliclazide metabolism is mediated by genetically polymorphic CYP2C9 and CYP2C19 enzymes. We investigated the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide. Twenty-seven Korean healthy volunteers were administered a single oral dose of gliclazide 80 mg. The plasma concentration of gliclazide was quantified for the pharmacokinetic analysis and plasma concentrations of glucose and insulin were measured as pharmacodynamic parameters. The pharmacokinetics of gliclazid...
Source: Archives of Pharmacal Research - April 25, 2023 Category: Drugs & Pharmacology Authors: Pureum Kang Chang-Keun Cho Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Chang-Ik Choi Jung-Woo Bae Source Type: research
